⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Quercetin
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-30 — An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer: Open-label pilot includes a D+Q arm in adult childhood-cancer survivors with p16INK4a and frailty endpoints — adds a survivor-aging indication to the quercetin senolytic clinical program; no results yet. [expert-opinion] (novelty: 3)
- 2026-10-06 — Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan: Same phenotypic screen situates quercetin within the broader natural-flavonoid senolytic scaffold being optimized via SR29384/SR31133-class derivatives, though quercetin itself was not the lead compound. [animal-model] (novelty: 3)
- 2026-10-05 — Therapeutic reversal of cellular senescence: A systematic review of senolytics, senomorphics and anti-ageing therapies in human clinical trials.: PRISMA systematic review of human trials highlights dasatinib+quercetin as the most-studied senolytic combination in humans but flags that current trials remain preliminary, with no established clinical efficacy or long-term safety for quercetin-containing regimens. [expert-opinion] (novelty: 3)
- 2026-04-02 — Ceramic-based biomaterials: Combining regeneration with anti-senescence.: Preclinical head-to-head comparison in osteoporotic bone regeneration: systemic dasatinib+quercetin was reportedly outperformed by hardystonite (ZnCS) silicate bioceramic scaffolds on BMSC senescence and bone regeneration endpoints — a context-specific limitation of D+Q when a local biomaterial anti-senescence modality is available at the bone niche. [animal-model] (novelty: 4)
- 2026-06-22 — Targeting Cellular Senescence Enhances Post-Burn Wound Healing in Aged Mice.: Aged-mouse burn-wound study: quercetin (as D+Q) reversed age-associated deficits in burn-wound healing, improving myofibroblast and type I collagen markers alongside senescent-cell clearance — adds acute burn injury in aged skin to quercetin’s senolytic indication set. [animal-model] (novelty: 3)
- 2026-10-01 — Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial.: Phase-2 RCT in fibrotic MASH: intermittent D+Q improved ≥1-stage liver fibrosis without MASH worsening in 47% vs 7% on placebo and resolved MASH more often, moving quercetin’s senolytic profile from preclinical/trial-design status to a positive paired-biopsy human RCT readout. [human-rct] (novelty: 4)
- 2026-09-15 — Radiation-induced atrial fibrillation is driven by cellular senescence via the GATA4 - NF-κB pathway and rescued by D/Q senolytic therapy.: Mouse radiation-induced AF study: quercetin (as D+Q) reversed atrial remodeling and AF susceptibility linked to GATA4–NF-κB-driven cardiomyocyte senescence — adds a cardiac electrophysiology/cardio-oncology indication to quercetin’s senolytic profile. [animal-model] (novelty: 3)
- 2026-09-18 — Cellular senescence is an early feature and therapeutic target in amyotrophic lateral sclerosis TDP-43mice.: TDP-43 ALS mouse study: quercetin (as D+Q) improved motor and neuromuscular outcomes, reduced plasma NfL, and preserved layer V cortical neurons — adds ALS to quercetin’s senolytic indication set. [animal-model] (novelty: 3)
- 2026-07-17 — Improving Physical Ability and Cellular Senescence Elimination in HIV: Phase II RCT of intermittent D+Q (12 weeks) in frail/prefrail adults 50+ with long-term suppressed HIV registered — first quercetin senolytic trial in a chronic-viral accelerated-aging population; protocol only, no results. [expert-opinion] (novelty: 3)
- 2026-03-25 — Senolytic therapy ameliorates high-fat diet-induced hippocampal senescence and cognitive decline in mice.: HFD/palmitate mouse study: quercetin (as D+Q) cleared hippocampal senescent cells and rescued diet-induced cognitive decline, adding an obesity–brain axis indication to quercetin’s senolytic profile. [animal-model] (novelty: 3)
- 2026-06-03 — Senolytics ameliorate cognitive decline in D-galactose-induced aging mice by inhibiting astrocytic cholesterol accumulation.: D-galactose aging-mouse study: quercetin (in D+Q combination) ameliorated cognitive decline via downregulation of astrocytic cholesterol biosynthesis, cutting astrocyte lipid accumulation and neuroinflammation — adds a cholesterol/lipid-pathway mechanism to quercetin’s senolytic profile. [animal-model] (novelty: 3)
- 2026-06-27 — Co-exposure to environmental lead and hypertension exacerbates anxiety and depression via mtDNA-mediated cGAS phase separation.: Mouse Pb+hypertension co-exposure study: quercetin (as part of D+Q senolytic combination) reversed prefrontal astrocyte senescence and anxiety/depression-like behavior linked to mtDNA-driven cGAS phase separation — extends quercetin’s senolytic role into an environmental–cardiometabolic neurobehavioral model. [animal-model] (novelty: 3)
- 2026-07-17 — Manganese overload as a previously underappreciated trigger of cellular senescence: Unraveling mechanisms and therapeutic rescue by the senolytic quercetin.: C. elegans and PC12 cell study: manganese overload induced cellular senescence (SA-β-gal, ROS, mitochondrial dysfunction, telomere attrition, p53/p21, STING signaling) and quercetin attenuated these changes — positions quercetin as a senolytic/senomorphic rescue in a metal-toxicity senescence model, not a healthspan outcome. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
Senescence-Associated Secretory Phenotype (SASP) and Atherosclerotic Plaque Inflammation: Natural Product-Based Interventions and Implications for Personalized Therapy.
10-nov-2026
novelty 2
per-area 2
strengthens
Is there a role for senotherapeutics in the treatment of giant cell arteritis?
07-oct-2026
novelty 2
per-area 2
mentions
Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan
06-oct-2026
novelty 3
per-area 3
strengthens
Therapeutic reversal of cellular senescence: A systematic review of senolytics, senomorphics and anti-ageing therapies in human clinical trials.
05-oct-2026
novelty 3
per-area 3
strengthens
Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial.
01-oct-2026
novelty 4
per-area 4
strengthens
An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer
30-sep-2026
novelty 3
per-area 3
strengthens
Mitochondrial-Targeted Phytochemicals in Reproductive Aging: Mechanisms and Translational Potential.
25-sep-2026
novelty 2
per-area 2
strengthens
Therapeutic Targeting of Inflammaging and Emerging Strategies for Managing Age-Related Multimorbidity: A Narrative Review.
19-sep-2026
novelty 2
per-area 2
mentions
Cellular senescence is an early feature and therapeutic target in amyotrophic lateral sclerosis TDP-43mice.
18-sep-2026
novelty 3
per-area 3
strengthens
The dimorphic brain in ischemic stroke: How sex and age shape molecular pathophysiology and therapeutic responsiveness.
16-sep-2026
novelty 2
per-area 1
mentions
Radiation-induced atrial fibrillation is driven by cellular senescence via the GATA4 - NF-κB pathway and rescued by D/Q senolytic therapy.
15-sep-2026
novelty 3
per-area 3
strengthens
The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health
12-aug-2026
novelty 2
per-area 2
mentions
Effects of Freeze-dried Grape Powder on Immune Profiles in Healthy Aging Adults
12-aug-2026
novelty 2
per-area 2
mentions
Improving Physical Ability and Cellular Senescence Elimination in HIV
17-jul-2026
novelty 3
per-area 3
strengthens
Manganese overload as a previously underappreciated trigger of cellular senescence: Unraveling mechanisms and therapeutic rescue by the senolytic quercetin.
17-jul-2026
novelty 3
per-area 3
strengthens
Dietary bioactive compounds and inflammaging: Pro-inflammatory triggers and geroprotective countermeasures.
09-jul-2026
novelty 2
per-area 2
strengthens
Quercetin alleviates MSG-induced oxidative toxicity and lifespan deterioration in Caenorhabditis elegans associated with SKN-1-gst-4 detoxification and DAF-16-dependent stress resilience.
09-jul-2026
novelty 2
per-area 2
strengthens
Macrophage senescence and programmed cell death in atherosclerosis: Mechanisms, cross-talk, and emerging therapeutic strategies.
02-jul-2026
novelty 2
per-area 2
strengthens
Co-exposure to environmental lead and hypertension exacerbates anxiety and depression via mtDNA-mediated cGAS phase separation.
27-jun-2026
novelty 3
per-area 3
strengthens
Targeting Cellular Senescence Enhances Post-Burn Wound Healing in Aged Mice.
22-jun-2026
novelty 3
per-area 3
strengthens
Senolytics ameliorate cognitive decline in D-galactose-induced aging mice by inhibiting astrocytic cholesterol accumulation.
03-jun-2026
novelty 3
per-area 3
strengthens
Ceramic-based biomaterials: Combining regeneration with anti-senescence.
02-apr-2026
novelty 4
per-area 4
strengthens
Senolytic therapy ameliorates high-fat diet-induced hippocampal senescence and cognitive decline in mice.
25-mar-2026
novelty 3
per-area 3
strengthens
Restoring NAD⁺-Sirtuins Signaling: A Novel Approach to Combat Male Reproductive Aging.
06-feb-2026
novelty 2
per-area 2
mentions